CompletedNot Applicable

Association of TLR7 Gene rs3853839 Polymorphism With Disease Severity in Alopecia Areata: A Case-Control Study

Egypt120 participantsStarted 2022-12-01

Plain-language summary

Alopecia areata is an autoimmune, non-scarring hair loss disorder characterized by variable clinical severity. Toll-like receptor 7 (TLR7) plays a key role in innate immune activation and autoimmune responses. The rs3853839 polymorphism of the TLR7 gene has been implicated in immune-mediated diseases. This study aims to evaluate the association between TLR7 rs3853839 polymorphism and susceptibility to alopecia areata, and to assess its correlation with disease severity measured by the Severity of Alopecia Tool (SALT) score. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria (Cases): * Clinical diagnosis of alopecia areata * Age ≥ 18 years * Both genders * Provision of written informed consent Inclusion Criteria (Controls): * Apparently healthy individuals * No personal or family history of autoimmune disease * Age- and sex-matched to patient group * Provision of written informed consent Exclusion Criteria: * Presence of other autoimmune or inflammatory disorders * Current systemic immunosuppressive therapy * Pregnancy or lactation * Refusal to participate Exclusion Criteria: \-

What they're measuring

Genotype and Allele Frequency Distribution of TLR7 rs3853839

Timeframe: Baseline

Trial details

NCT IDNCT07454876

SponsorBenha University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-10

View on ClinicalTrials.gov More Alopecia Areata trials